Plerixafor Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 20 mg/mL
Reference Brands: Mozobil (USA/EU)
Category:
Critical Care
Plerixafor is available in Injection
and strengths such as 20 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Plerixafor is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Plerixafor can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Plerixafor, marketed under the brand name Mozobil, is a targeted immunostimulant used to mobilize hematopoietic stem cells into the bloodstream for patients undergoing stem cell transplantation. It is primarily indicated for individuals with lymphoma or multiple myeloma who are preparing for autologous stem cell transplantation. The mobilized stem cells are collected from peripheral blood and later reinfused into the patient to restore healthy bone marrow function.
Plerixafor works by selectively blocking the CXCR4 chemokine receptor on hematopoietic stem cells, disrupting their interaction with the bone marrow niche. This mechanism allows stem cells to move from the bone marrow into peripheral circulation, where they can be efficiently collected. While granulocyte colony-stimulating factor (G-CSF) is commonly used for stem cell mobilization, about 15–20% of patients do not respond adequately. The combination of plerixafor with G-CSF significantly increases the likelihood of successful mobilization, ensuring enough stem cells are available for transplantation.
Originally developed by AnorMED and later acquired by Genzyme, Mozobil has become a critical tool in modern hematology, providing an effective and reliable method to improve transplantation outcomes in patients with hematologic malignancies. Its use is carefully supervised in specialized clinical settings to maximize efficacy and safety.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing